Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | bb2121: a promising outlook for the future of multiple myeloma

The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.